πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

7,888 results for β€œ1” Clear

  1. Olodaterol (BI 1744)

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  2. Olpasiran, Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  3. Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naΓ―ve dermatomyositis.

    phase 3 small molecule active

    1 trial

  4. Omecamtiv Mecarbil, Omecamtiv Mecarbil, Matching Placebo, Omecamtiv Mecarbil

    Cytokinetics (Ireland) Limited

    Heart Failure With Reduced Ejection Fraction

    phase 3 small molecule active

    1 trial

  5. Omicron COVID-19 Vaccine (Vero Cell), Inactivated

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 3 mab active

    2 trials

  6. Omvoh 300 mg concentrate for solution for infusion, Omvoh 100 mg solution for injection in pre-filled syringe

    Eli Lilly Co.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  7. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer InfusionslΓΆsung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  8. Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  9. Opaganib

    RedHill Biopharma

    COVID-19

    phase 3 small molecule terminated

    2 trials

  10. Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

    Chiesi Farmaceutici S.p.A

    Fabry disease (Ξ±-galactosidase A deficiency)

    phase 3 other active

    1 trial

  11. Oral treprostinil (UT-15C) sustained release tablets

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    2 trials

  12. Orelabrutinib, Placebo tablets match with that of orelabrutinib (ICP-022) tablets in appearance, shape, size, and weight.

    Zenas BioPharma

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  13. Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  14. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  15. Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets

    Dr. Falk Pharma GmbH

    eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

  16. Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  17. Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  18. Otezla 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279), Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), ZASOCITINIB

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  19. Oxygen (15-O) Water

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 3 small molecule completed

    1 trial

  20. Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl 0.23 mg , Ozanimod HCl 1 mg , Ozanimod HCl 0.0575 mg , Ozanimod HCl 0.25 mg, Fingolimod 0.25 mg capsule, Fingolimod 0.5 mg capsule

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  21. Ozanimod, Ozanimod

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  22. Ozanimod, Ozanimod

    Celgene Europe Limited

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  23. Ozanimod, Ozanimod, Ozanimod

    Bristol-Myers Squibb Australia Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  24. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources